{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:14:37Z","timestamp":1787764477041,"version":"build-2784847793"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune condition that can involve various organ systems. Ocular involvement, though uncommon, may present as the initial or even sole manifestation. Orbital inflammatory pseudotumor, particularly its sclerosing subtype, can pose significant diagnostic and therapeutic challenges due to its steroid dependence and potential for recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 72-year-old Chinese man presented with a 6-month history of recurrent headaches. He later developed bilateral exophthalmos and progressive vision loss despite initial treatment. His past medical history included type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient initially tested positive for both p-ANCA and c-ANCA, with markedly elevated anti-myeloperoxidase and proteinase 3 antibody levels. Imaging revealed bilateral orbital masses consistent with orbital inflammatory pseudotumor, and biopsy confirmed sclerosing orbital inflammatory pseudotumor. Despite serological remission, clinical symptoms worsened during steroid tapering, suggesting steroid dependence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was initially treated with high-dose corticosteroids and oral cyclophosphamide. Although symptoms improved transiently, relapse occurred upon tapering steroids. Rituximab (RTX; 500\u2009mg weekly for 4 weeks) was then administered as second-line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome:<\/jats:title>\n                    <jats:p>The patient experienced significant improvement following RTX therapy, which allowed successful steroid tapering. No further relapse occurred during short-term follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case illustrates the limitations of cyclophosphamide-based regimens in managing steroid-dependent ANCA-associated orbital disease. RTX may be a more effective alternative in relapsing or refractory cases, particularly when ocular symptoms persist despite ANCA seronegativity. Early recognition and individualized immunosuppressive therapy are essential for preserving vision and improving outcomes in ocular ANCA-associated vasculitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045044","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:08:36Z","timestamp":1759781316000},"page":"e45044","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of anti-neutrophil cytoplasmic antibody-associated inflammatory pseudotumour with rituximab: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0983-3555","authenticated-orcid":false,"given":"Lan","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, The First People\u2019s Hospital of Yibin, Yibin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, West China Hospital Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Jiange First People\u2019s Hospital, Guangyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, West China Hospital Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1590\/1516-3180.2018.0258060219","article-title":"Analysis on the risk factors for organ damage in patients with systemic lupus erythematosus: a cross-sectional single-center experience.","volume":"137","author":"\u017divkovi\u0107","year":"2019","journal-title":"Sao Paulo Med J"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICU.0b013e32834bdfe2","article-title":"Ocular manifestations of systemic disease.","volume":"22","author":"Schmidt","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.crad.2011.03.018","article-title":"Idiopathic orbital pseudotumour.","volume":"66","author":"Ding","year":"2011","journal-title":"Clin Radiol"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0974-9233.53370","article-title":"Orbital pseudotumor: distinct diagnostic features and management.","volume":"15","author":"Chaudhry","year":"2008","journal-title":"Middle East Afr J Ophthalmol"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0033-8389(05)70084-1","article-title":"Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation.","volume":"37","author":"Weber","year":"1999","journal-title":"Radiol Clin North Am"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamaophthalmol.2017.1581","article-title":"Consensus on diagnostic criteria of idiopathic orbital inflammation using a modified Delphi approach.","volume":"135","author":"Mombaerts","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00347-021-01459-5","article-title":"Idiopathische orbitale Entz\u00fcndungen.","volume":"118","author":"Lieb","year":"2021","journal-title":"Der Ophthalmologe"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/01676830.2012.681749","article-title":"Evaluation of classification systems for nonspecific idiopathic orbital inflammation.","volume":"31","author":"Bijlsma","year":"2012","journal-title":"Orbit"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2020.09.012","article-title":"Histopathologic findings in idiopathic orbital myositis.","volume":"128","author":"Ben Artsi","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0039-6257(97)81996-0","article-title":"What is orbital pseudotumor?","volume":"41","author":"Mombaerts","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"R11-20260526","first-page":"672","article-title":"Rituximab for treatment of autoimmune hemolytic anemia.","volume":"49","author":"Kuzmanovic","year":"2012","journal-title":"Indian Pediatr"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00403-009-0967-1","article-title":"Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin\u2019s lymphoma.","volume":"301","author":"Colovic","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis.","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases.","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jamaophthalmol.2013.8179","article-title":"Rituximab therapy for refractory orbital inflammation: results of a phase 1\/2, dose-ranging, randomized clinical trial.","volume":"132","author":"Suhler","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/01676830.2021.1874424","article-title":"Long-term follow up of systemic rituximab therapy as first-line and salvage therapy for idiopathic orbital inflammation and review of the literature.","volume":"41","author":"Abou-Hanna","year":"2022","journal-title":"Orbit"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1097\/IOP.0000000000001843","article-title":"Rituximab therapy for recalcitrant idiopathic sclerosing orbital inflammation.","volume":"37","author":"Yazici","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3109\/09273948.2013.863943","article-title":"Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab.","volume":"23","author":"Abell","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders.","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action.","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3389\/fimmu.2018.00765","article-title":"Are anti-retinal autoantibodies a cause or a consequence of retinal degeneration in autoimmune retinopathies?","volume":"9","author":"Adamus","year":"2018","journal-title":"Front Immunol"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajo.2017.12.004","article-title":"Characteristics and visual outcome of refractory retinal vasculitis associated with antineutrophil cytoplasm antibody-associated vasculitides.","volume":"187","author":"Lin","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/ar2923","article-title":"T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?","volume":"12","author":"Wilde","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/ijms23010387","article-title":"B lineage cells in ANCA-associated vasculitis.","volume":"23","author":"Merino-Vico","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update.","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R29-20260526","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/rheumatology\/kez071","article-title":"Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients.","volume":"58","author":"Durel","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20260526","doi-asserted-by":"crossref","first-page":"10","DOI":"10.22336\/rjo.2021.3","article-title":"Therapy of ocular complications in ANCA+ associated vasculitis.","volume":"65","author":"Macarie","year":"2021","journal-title":"Rom J Ophthalmol"},{"key":"R31-20260526","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/09273940802596500","article-title":"Recalcitrant granulomatous sclerouveitis in a patient with granulomatous ANCA-associated vasculitis.","volume":"17","author":"Levy-Clarke","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"R32-20260526","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archophthalmol.2011.62","article-title":"Granulomatous choroiditis in Wegener granulomatosis.","volume":"129","author":"Proia","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R33-20260526","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archopht.1990.01070080087041","article-title":"Ocular manifestations of patients with circulating antineutrophil cytoplasmic antibodies.","volume":"108","author":"Pulido","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"R34-20260526","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/archopht.1996.01100130342023","article-title":"Microscopic polyangiitis with ocular involvement.","volume":"114","author":"Caster","year":"1996","journal-title":"Arch Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:00:57Z","timestamp":1779804057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045044","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2025-04-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}